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Oral Presentations S1711) At least one 8/8 HR matched donor exists on BTMR
2) No potential 8/8 HR donors exist
3) Potential 8/8 HR donors exist
PP searches falling into category 3 (accrued untilN5 200 per race)
then had anHLA search strategy expert rank potential donors within
BTMRinorder of theirmatching likelihood.Previously storeddonor
sampleswereHRHLA tested in order of ranking and evaluated to de-
termine match status. Consecutive rounds of donor sample testing
were performed until either an 8/8 matched donor was identified or
no potential donors with stored samples remained.
Results: The table below shows the 8/8 HRmatch rate of cases to be
68% for CAU, 42% forHIS, 45% for API, and 27% for AFA. Careful
review of the cases ‘‘Pending further testing; no stored sample’’ sug-
gests that few additional cases would yield 8/8 HR matches.
CAU PP HIS PP API PP AFA PP8/8 HR Matched 258 (68%) 128 (42%) 122 (45%) 105 (27%)
Pending Further Testing;
No Stored Sample48 (13%) 65 (21%) 57 (21%) 54 (14%)No 8/8 HR Match 71 (19%) 114 (37%) 91 (34%) 231 (59%)
TOTAL 377 307 270 390Conclusions:This studyprovides a true8/8HRmatchrateestimate for
CAU,HIS, API, and AFA patients through BTMR, which has not been
accomplished previously. These results demonstrate the racial disparity
in HLA match rates and can be used to inform patients searching
BTMR.This studyalsoprovides vital information fordonor recruitment
and availability efforts. Results provide a baseline match rate that can be
further supplemented using the additional worldwide URD inventory.
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Haploidentical HSCT using post transplant cyclophosphamide
(CY) for elimination of alloreactive lymphocytes has been reported
as a safe option for patients lacking an HLA identical donor. We re-
port an alternate approachwith the following salient differences: mye-
loablative vs non-myeloablative conditioning, peripheral blood rather
than marrow stem cell source, no exposure vs exposure of HSC to cy-
clophosphamide, higher fixed number of CD3 cells versus a lower var-
iable number of CD3 cells in each graft. Results are reported nowwith
a followed up of 18-46 months.
Table 1. Patient Characteristics-2 Step ApproachAge 52 (19-67)AML 16Remission 7Resistant/PIF 9Biphenotypic Leukemia
(Active Disease)1ALL 4CR2 (ph-) 3Persistent Disease (PH+) 1MDS 2NHL Resistant 3SAA 1HLA MM (GVH Direction)4 133 112 20 1Patients received 12 Gy of total body irradiation (TBI), followed by
a donor lymphocyte product (DLI) containing 2  10e8 CD31
cells/kg (Step 1). This large dose of haploidentical lymphocytes re-
sulted in fever (median temperature 103.8f), diarrhea and rash. CY
60 mg/kg was given on days -3 and -2 resulting in resolution of symp-
toms. Tacrolimus and MMF were begun on day-1. A CD 34 selected
donor product was infused on day 0 (Step 2). Two of the 27 patients
died of toxicity and infection before day 14. Of the remaining 25 pa-
tients, 23 had complete engraftment while two with pre-existing
anti-donor HLA antibodies failed to engraft. Only 2 of 25 (8%) pa-
tients developed severe acuteGVHD, 3 of 25 (12%) developed limited
chronic GVHD, and no patient died of GVHD. Only two of 25 pa-
tients (8%) died of infection. Of 16 disease-free patients surviving 6
months from HSCT, median CD41 count at day 100 was 105 cells/
ml (range 10-403). Eight of 25 (32%) patients relapsed after HSCT.
Probability of survival (OS) at 1 and 3 years post transplant is 52%
and 48% respectively. All surviving patients are disease-free. OS at 3
years is 75% for patients transplanted inCR, but only 27% for patients
transplanted with active disease. KIR mismatching was not correlated
with relapse rates. In contrast, child tomother transplants for AMLap-
pear to be relapsing at higher rates than other combinations (66% vs
14%). In the context of CY tolerization, a dose of 2 10e8/kg T-cells
resulted inconsistent engraftment, prompt immune reconstitution, lit-
tle severe GVHD, acceptable toxicity, and encouraging overall sur-
vival, particularly in patients transplanted in CR. Using this 2-step
platform allows us to explore the use of alternate agents for the elimi-
nationof alloreactive lymphocytes, increase the lengthof time between
DLI andCY, and to employ twodonor strategies to improveoutcomes
in high risk patients.
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USING MYELOABLATIVE OR REDUCED-INTENSITY PRECONDITIONING
REGIMEN
Ikegame, K., Yoshihara, S., Kaida, K., Taniguchi, K., Inoue, T., Kato, R.,
Fujioka, T., Tamaki, H., Okada,M., Soma, T., Taniguchi, Y., Ogawa,H.
Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
Background: Related haploidentical donors, as cord blood, can be
alternative donor sources in stem cell transplantation (SCT). Severe
GVHD, however, has interfered the progress of haploidentical SCT
(haploSCT). To deal with this strong GVHD, T cell depletion has
usually been used in US and European countries. In order to pursue
the controllable GVL effect by T cells, we have performed unmanip-
ulated haploSCTusingmyeloablative or reduced intensity precondi-
tioning regimen accompanied with intensified GVHD prophylaxis.
In this meeting, we will summarize our experience of haploSCT
for more than ten years.
Patients: From August 1998 to September 2010, we have performed
351 cases of haploSCT (all cases were HLA 2-3 antigen mismatched
in GVH direction). Patients’ characteristics are sex: male 186, female
168, age: 16-65 years old (median 39), disease: AML/MDS 149, ALL
81, ML 67, others 54. 83% of cases underwent SCT in non-complete
remission (non-CR) state. Patients under 45 years old underwentmye-
loablative preconditioning regimen consisting of FLU/CA/CY/
TBI8Gy (haplo-full, n 5 100), and patients over 45 years old or
with comorbidities or repetitive SCT (including second to fifth
SCT) underwent reduced intensity preconditioning regimen consist-
ing of FLU/(CA)/BU/ATGor FLU/(CA)/MEL/ATG (haplo-mini, n
5 251). High dose Ara-C (CA) was optional to reduce tumor burden.
As ATG, ATG (Fresenius) 8mg/kg, or thymoglubulin (genzyme) 2-
4mg/kg were used. GVHD prophylaxis consisted of taclolimus
(TAC), methylprednisolone (mPSL) 2mg/kg/day, short term MTX,
and mycophenolate mofetil (MMF) 15mg/kg/day in haplo-full, and
TAC, mPSL 1mg/kg/day in haplo-mini, respectively. For elderly pa-
tients over 50 years old in haplo-mini, MMF was added.
Results: Hematopoietic engraftment in haploSCT was as rapid as
that in HLA-identical SCT, except ten cases of graft rejection. Acute
GVHD (grade II-IV) was observed in 30%. Overall survival in five
years is 30% in haplo-full and 40% in haplo-mini, respectively. If
limited to CR cases, overall survival reached over 60% in haplo-
mini. There is no difference in survival rate among patients’ diseases.
Discussion: Unmanipulated haploSCT is feasible and effective for
refractory diseases. ATG dose used in haplo-mini is critical, and
rather low compared with that of European cases reported so far.
